

RECEIVED

JUN - 3 2011

DNMS

U.S. Nuclear Regulatory Commission
Region IV
611 Ryan Plaza Dr., Suite 400
Arlington, TX 76011-4005

May 27, 2011
License 25-12453-02
Subject: License Amendment

To Whom It May Concern:

Please add James Kennedy Tarver, MD, as an authorized user to our license in the same categories as he is on North Carolina State License 016-0634-1.

Please remove Mary Murphy, MD from the authorized user list effective July 1, 2011.

If you have any questions or concerns, please contact me at 406-495-6770, or call my cell phone at 406-465-8017.

Sincerely,



Rod Knable, ARRT (N)
Radiation Safety Officer
St. Peter's Hospital
2475 Broadway
Helena, MT 50601

h 575309



 **St. Peter's Hospital**
2475 Broadway Helena, MT 59601

Facsimile Network
Telefax Message

Date: 6/13/11

To: NRC

Facility/Individual to whom information is being faxed

817 860-8188

Tax Number

Phone Number _____

Michelle Simmons

Contact Person at receiving facility

From:

Department

Nuclear Medicine St. Peter's Hsp

406 4K4-2113

Helena, MT

Fax Number

Phone Number

Number RodKnable Phone Number 406-465-8017

Contact person in department sending information

406-495-6770

Number of pages being faxed (including this page): 12

Copy 2 licenses

Comments: & amendment request letter

We were unable to download the CD received from your facility and are requesting films for the following patient:

Last Name _____ First Name _____ MI _____

Date of Birth: _____ / _____ / _____

Thanks, Michelle!

CONFIDENTIALITY NOTICE: The information transmitted by this facsimile is considered privileged and confidential and is intended only for the use of the individual or entity named. If the reader of this message is not the intended recipient, you should be aware that any dissemination, distribution, or copying of this communication is strictly prohibited. **If you received this communication in error, please immediately notify us by telephone and disregard this facsimile.** Thank you.



St. Peter's Hospital

2475 Broadway • Helena, Montana 59601 • Phone: (406) 442-2480 • www.stpetes.org

United States
Nuclear Regulatory Commission
Region IV
612 East Lamar Boulevard, Suite 400
Arlington, Texas 76011-4125

License 25-12453-02

June 13, 2010

Subject: Amendment request to add an Authorized User

To Whom It May Concern:

Please add James C. Seibly, MD, as an Authorized User in all categories that he was authorized on NRC License 24-18655-01. This license expired on August 31, 2010 and I have discovered that their current license does not list him as an authorized user.

During the time of his being on the above license and until now, Dr. Seibly has continued his experience as a Radiologist in both Diagnostic Radiology and Nuclear Medicine.

You can contact me at 406-495-6770, if you have any questions.

Sincerely,

Rod Knable, ARRT(R)(N)
Radiation Safety Officer

Enclosure: NRC License 24-18655 Amendment No. 42

Jun. 1. 2011 9:50AM MEDICAL IMAGE

No. 2257 P. 2

NUC 3 41261254

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 5 PAGES
Amendment No. 42

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 163 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee - Midwest Division - IRHC, LLC (d/b/a Independence Regional Health Center) 1509 W. Truman Road Independence, MO 64050	In accordance with the letter dated July 8, 2005, - License number 24-18655-01 is amended in its entirety to read as follows: - Expiration date August 31, 2010 Docket No. 090-13694 Revolving No.
--	---

6. Byproduct, source, and/or special nuclear material
- | | | |
|---|---|--|
| <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 35.400</p> <p>E. Any byproduct material permitted by 10 CFR 35.600</p> <p>F. Any byproduct material permitted by 10 CFR 31.11</p> <p>G. Gadolinium-153</p> | <p>Chemical and/or physical form</p> <p>A. Any (excluding generators)</p> <p>B. Any (excluding generators)</p> <p>C. Any (excluding generators)</p> <p>D. Any (excluding generators)</p> <p>E. Sealed sources permitted by 10 CFR 35.500</p> <p>F. Prepackaged Kits</p> <p>G. Sealed sources (North American Scientific, Inc. Model 3601)</p> | <p>Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. As needed</p> <p>D. As needed</p> <p>E. As needed</p> <p>F. As needed</p> <p>G. 4 sources, not to exceed 300 millicuries each</p> |
|---|---|--|

9. Authorized Use:

- Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- Any imaging and localization study permitted by 10 CFR 35.200 (excluding generators).
- Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

Jun. 1. 2011 9:50AM MEDICAL IMAGE

No. 2257 P. 3

NRC FORM 374A		U.S. NUCLEAR REGULATORY COMMISSION		PAGE 2 of 8 PAGES	
MATERIALS LICENSE SUPPLEMENTARY SHEET			License Number 24-18855-01		
			Docket or Reference Number 030-13894		
			Amendment No. 42		
D. Any manual brachytherapy procedure permitted by 10 CFR 35.400. E. Diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g). F. In vitro studies. G. Two sources to be used in Adac Laboratories Transmission Line Source Housing VANTAGE device for medical radiography in humans. Two sources in shipping containers for replacement of the sources.					
CONDITIONS					
10. Licensed material shall be used at the licensee's facilities located at 1508 W. Truman Road, Independence, Missouri. 11. The Radiation Safety Officer for this license is Robert F. Thompson, M.D. 12. Licensed material is only authorized for use under the supervision of:					
A. Individuals permitted to work under license in accordance with 10 CFR 35.13 and 35.14. B. The following individuals are authorized to use the materials and types indicated:					
<u>Authorized Users</u>			<u>Materials and Use</u>		
Jon E. Gustafson, M.D.			10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy), 35.500, 31.11, and gadolinium-153 in VANTAGE device for medical radiography.		
David E. Hazuka, M.D.			10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy), 35.500, 31.11, and gadolinium-153 in VANTAGE device for medical radiography.		
Stephen R. Kunz, M.D.			10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy), 35.500, 31.11, and gadolinium-153 in VANTAGE device for medical radiography.		

Jun. 1. 2011 9:50AM MEDICAL IMAGE

No. 2257 P. 4_a

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 of 6 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
24-18855-01Docket or Reference Number
030-13994

Amendment No. 42

George William Pagson, M.D.

10 CFR 35.200, (limited to cardiovascular clinical procedures) and gadolinium-153 in VANTAGE device for medical radiography.

Richard A. Morrison, M.D.

10 CFR 35.400 and 35.500.

Gwendolyn Ramsey Amett, M.D.

10 CFR 35.100, 35.200, 35.300, 35.600, 31.11, and gadolinium-153 in VANTAGE device for medical radiography.

Robert F. Thompson, M.D.

10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy), 35.600, 31.11, and gadolinium-153 in VANTAGE device for medical radiography.

Richard L. Cronmeyer, M.D.

10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma therapy), 35.600, 31.11, and gadolinium-153 in VANTAGE device for medical radiography.

Paul Ren Chu, M.D.

10 CFR 35.200 (limited to cardiovascular clinical procedures).

Stephen A. Bloom, M.D.

10 CFR 35.200 (limited to cardiovascular clinical procedures) and gadolinium-153 in VANTAGE device for medical radiography.

Gordon Stillie, D.O.

10 CFR 35.400.

James P. McGraw, M.D.

10 CFR 35.200 (limited to cardiovascular clinical procedures), and gadolinium-153 in VANTAGE device for medical radiography.

Thomas L. Rosamond, M.D.

10 CFR 35.200 (limited to cardiovascular clinical procedures), and gadolinium-153 in VANTAGE device for medical radiography.

Alan Schneider, M.D.

10 CFR 35.200 (limited to cardiovascular clinical procedures), and gadolinium-153 in VANTAGE device for medical radiography.

Mark J. Lavín, M.D.

10 CFR 35.100, 35.200, 35.300 and 31.11.

Jun. 1, 2011 9:51AM MEDICAL IMAGE

No. 2257 P. 5

NRC FORM 374A		U.S. NUCLEAR REGULATORY COMMISSION	PAGE 4 of 8 PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET		License Number	24-19486-01
		Docket or Reference Number	030-13994
		Amendment No. 42	
William G. Jensen, M.D. 10 CFR 35.100, 35.200, 35.300, and 31.11 and gadolinium-153 in VANTAGE device for medical radiography. Kenneth M. Altieri, M.D. 10 CFR 35.100, 35.200, 35.300, 31.11 and gadolinium-153 in VANTAGE device for medical radiography. Joseph J. Varriano, M.D. 10 CFR 35.100, 35.200, 35.300, 31.11 and gadolinium-153 in VANTAGE device for medical radiography. James C. Seibly, M.D. 10 CFR 35.100, 35.200, 35.300, 31.11 and gadolinium-153 in VANTAGE device for medical radiography. Matthew R. Caterino, M.D. 10 CFR 35.100, 35.200, 35.500, 31.11, and gadolinium-153 in VANTAGE device for medical radiography. John M. Sheldon, M.D. 10 CFR 35.100 and 35.200 (excluding xenon-133), and thyroid carcinoma), 35.500 and 31.11. Maynard C. Jones, M.D. 10 CFR 35.100 and 35.200 (excluding xenon-133), 31.11 and gadolinium-153 in VANTAGE device for medical radiography. Ronald Hubbell, M.D. 10 CFR 35.100, 35.200, 35.300 (limited to iodine-131, strontium-89 and samarium-153), 35.500 and 31.11. Dipak Shah, M.D. 10 CFR 35.100, 35.200 (excluding generators), 35.500, and 31.11. Michael J. Matis, M.D. 10 CFR 35.100, 35.200 (excluding generators) and 31.11. David Mena, M.D. 10 CFR 35.100, 35.200, 35.500 and 31.11. Michael N. Roys, M.D. 10 CFR 35.100, 35.200 (excluding generators) and 31.11.			
13. Notwithstanding the provisions of Section 35.49 "Suppliers" of Title 10, Code of Federal Regulations, the licensee is authorized to receive 10 CFR Part 35.400 material from NRC License Number 24-19486-02 in accordance with Facsimile dated November 17, 2000. 14. In addition to the possession limits in item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.			

Jun. 1. 2011 9:51AM MEDICAL IMAGE

No. 2257 P. 6

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION	PAGE 6 of 6 PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET		License Number 24-19853-01
		Docket or Reference Number 030-13894
		Amendment No. 42

15. A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed 6 months or at such other intervals as specified by the certificate of registration referred to in 10 CFR 32.210.

B. In the absence of a certificate from a transferor indicating that a leak test has been made within 6 months prior to the transfer, a sealed source received from another person shall not be put into use until tested.

C. Sealed sources need not be leak tested if are in storage, and are not being used. However, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

D. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.25(e)(2), and the source shall be removed immediately from service and decontaminated, repaired or disposed of in accordance with Commission regulations.

E. The licensee is authorized to collect samples for analysis but not perform the analysis. Analysis of leak samples may be performed by persons specifically licensed by the Commission or an Agreement State to perform such analysis.

16. Sealed sources containing licensed material shall be opened or sources removed from source holders by the licensee.

17. The licensee shall conduct a physical inventory every 3 months to account for all sources and/or devices received and possessed pursuant to 10 CFR 35.53, 10 CFR 35.400 and 10 CFR 35.500 and every 6 months for all other sources and/or devices. Records of inventories shall be maintained for 5 years from the date of each inventory, and shall include the information required in 10 CFR 35.59(g).

18. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

Jun. 1. 2011 9:51AM MEDICAL IMAGE

No. 2257 P. 7

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION	PAGE 6 of 6 PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 24-16855-01	
	Docket or Reference Number 030-13994	
	Amendment No. 42	
10. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.20. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the regulations.		
A. Application dated July 21, 2000 (excluding AFT-210-15 and 12.1); B. Facsimile dated November 17, 2000 (excluding pages 7 and 8); and July 30, 2002; and C. Letters dated April 15, 2002, March 26, 2003, and April 15, 2003 (with enclosure).		
		
FOR THE U.S. NUCLEAR REGULATORY COMMISSION		
Date <u>OCT 06 2005</u>	By <u>William P. Reichhold</u> Materials Licensing Branch Region III	

May. 31. 2011 8:03AM Sun VAN A-KAY

No. 9081 P. 5
no. 2033 P. 1

Page 1 of 4



**RADIOACTIVE MATERIALS BRANCH
RADIATION PROTECTION SECTION
N. C. DEPARTMENT OF ENVIRONMENT AND NATURAL RESOURCES**

RADIOACTIVE MATERIALS LICENSE

Pursuant to North Carolina Regulations for Protection Against Radiation and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, own, possess, transfer, and import radioactive materials listed below; and use such radioactive material for the purpose(s) and at the place(s) designated below. This license is subject to all applicable rules and regulations of the North Carolina Department of Environment and Natural Resources now and hereafter in effect and to any conditions specified below.


Tanner

1. Licensee Name: Carteret General Hospital		3. License No: 016-0634-1		License Type 0130						
2a. Mailing Address: 3500 Arendell Street Morehead City, NC 28557		4. Expiration Date: January 31, 2015								
b. Physical Address: 3500 Arendell Street Morehead City, NC 28557		<table border="1"> <tr> <td>☒ New License</td> <td>☐ Routine Administrative</td> <td>☐ Corrected Copy</td> </tr> <tr> <td>☐ Renewal</td> <td>☐ Termination</td> <td>☐ Termination</td> </tr> </table>			☒ New License	☐ Routine Administrative	☐ Corrected Copy	☐ Renewal	☐ Termination	☐ Termination
☒ New License	☐ Routine Administrative	☐ Corrected Copy								
☐ Renewal	☐ Termination	☐ Termination								
c. Radiation Safety Officer: Kenneth R. McBride		5. a. Amendment No.: 39								
		b. Issuance Date: January 24, 2010								
6. Radioactive Material (element and mass no.)	7. Chemical and/or Physical Form	8. Maximum Amount of Radioactivity and/or Quantity of Radioactive Material which Licensee May Possess at Any One Time.								
A. Any radioactive material permitted under 15A NCAC 11.0361(a)	A. Any form	A. As necessary for medical use								
B. Any radioactive material authorized under 15A NCAC 11.0321(b).	B. Any form as specified in 15A NCAC 11.0321(b).	B. No single source to exceed the limits specified in 15A NCAC 11.0321(b).								
C. Strontium 90	C. Sealed Source	C. No single source to exceed 50 millirads								
9. Authorized Use:										
A. To be used for the purposes of medical diagnosis and therapy in accordance with a written directive from an authorized user (if applicable).										
B. To be used as check, calibration, transmission, and reference standards.										

CONDITIONS

10. The authorized place of receipt and use of radioactive material is the licensee's address stated in item 2.b. above.
11. The licensee shall comply with the provisions of 15A NCAC 11.1600 "Standards for Protection Against Radiation," and 15A NCAC 11.1000 "Notices, Instructions, Reports and Inspections," and 15A NCAC 11.0700 "Use of Sealed Radioactive Sources in the Healing Arts" (when applicable). (The North Carolina Regulations for Protection Against Radiation are contained in 15A NCAC 11.)
12.
 - A. The licensee shall comply with the provision of 15A NCAC 11.0321 in the procurement and use of radioactive materials authorized in this license.
 - B. Radiopharmaceuticals and kits or generators used in their preparation shall be procured from a supplier who manufactures or repackages the product under appropriate pharmaceutical controls related to assay, identity, quality, purity, sterility, and pyrogenicity.

May. 31. 2011 8:03AM.42nm VCM X-RAY

No. 9081 P. 6
No. 2033 P. 2Division of
Environmental Health

**RADIOACTIVE MATERIALS BRANCH
RADIATION PROTECTION SECTION
N. C. DEPARTMENT OF ENVIRONMENT AND NATURAL RESOURCES**

Page 2 of 4
License No.: 016-0634-1

RADIOACTIVE MATERIALS LICENSE

CONDITIONS (continued):

13. The licensee is authorized to receive, acquire, possess, transfer, and use *in vitro* clinical or laboratory testing kits as authorized in 15A NCAC 11 .0314 without filing agency forms as required by 15A NCAC 11 .0314(b), provided that the licensee is subject to the other provisions of 15A NCAC 11 .0314.
14. A. Sealed radioactive sources owned or possessed for calibration and reference standards shall be tested for leakage and/or contamination in accordance with 15A NCAC 11 .0321(c).
B. The licensee shall conduct a quarterly physical inventory to account for all sealed sources received and possessed under this license which are used for the calibration/reference of the dose calibrator and patient imaging equipment. Records of the inventories shall be maintained for inspection by the agency and shall include the quantities and kinds of radioactive material, location of the sources, and the date of the inventory.
15. Sealed sources containing radioactive material shall not be opened by the licensee.
16. A. The licensee is hereby authorized to use Molybdenum 99 / Technetium 99m generators for preparing Technetium 99m radiopharmaceuticals in accordance with 15A NCAC 11 .0361.
B. Radioactive materials shall not be used on humans until its pharmaceutical quality and assay have been established.
17. A. Radioactive material for imaging and localization diagnostic studies (15A NCAC 11. 0117(a) and 10 CFR 35.200 uses) shall be used by:

Alfred James Beyer, MD	Samuel Joseph Huff, MD	Richard B. Caswell, Jr, MD
William C. Corey, DO	Elizabeth Gilbert D'Angelo, MD	Catherine Joyce Everett, MD
Christopher Warren Flye, MD	Donald Charles Jackson, MD	James C. Lorentzen, MD
Michael A. Papagikos, MD	Stephen Nelson Sides, II, MD	Timothy Sloan, MD
John A. Snyder, MD	Thomas Stohrer, MD	James Kennedy Tarver, MD
Garret Pinkney Young, MD		
- B. Radioactive material for the therapeutic use of radioactive materials in unsealed form except I-131 (15A NCAC 11. 0117(a) and 10 CFR 35.300 uses) shall be used by:

Martin B. Meyerson, MD	Charles Neal, MD	Patrick D. Maguire, MD
Michael A. Papagikos, MD		
- C. Radioactive material for the therapeutic use of quantities of I-131 greater than 33mCi (1.22GBq) in unsealed form (15A NCAC 11. 0117(a) and 10 CFR 35.394 uses) shall be used by:

Alfred James Beyer, MD	Samuel Joseph Huff, MD	William C. Corey, DO
Elizabeth Gilbert D'Angelo, MD	Catherine Joyce Everett, MD	Christopher Warren Flye, MD
Donald Charles Jackson, MD	James C. Lorentzen, MD	Patrick D. Maguire, MD
Martin B. Meyerson, MD	Charles Neal, MD	Stephen Nelson Sides, II, MD
Timothy Sloan, MD	John A. Snyder, MD	Thomas Walter Stohrer, MD
Garret Pinkney Young, MD		
- D. Radioactive material for the therapeutic use of sealed radioactive sources in ophthalmic devices containing Sr-90 (15A NCAC 11. 0117(a) and 10 CFR 35.400) shall be used by:

Patrick D. Maguire, MD	Martin B. Meyerson, MD	Charles Neal, MD
Michael A. Papagikos, MD		

May. 31. 2011 8:03AM - 22MM LHM X-RAY

No. 9081 P. 7
No. 2033 P. 3

**RADIOACTIVE MATERIALS BRANCH
RADIATION PROTECTION SECTION
N. C. DEPARTMENT OF ENVIRONMENT AND NATURAL RESOURCES**

Page 3 of 4
License No.: 016-0634-1

RADIOACTIVE MATERIALS LICENSE

CONDITIONS (continued):

17. L. Notwithstanding A., through D., above:

- i. Physicians authorized for the use of radioactive material for imaging and localization diagnostic studies are also authorized to use radioactive material for uptake, dilution and excretion diagnostic studies.
- ii. Physicians authorized for the therapeutic use of radioactive material are also authorized for the use of radioactive material for imaging and localization diagnostic studies and uptake, dilution and excretion diagnostic studies provided the physicians have training in the elution of generators, assaying the eluate for radiological purity, the preparation of radiopharmaceuticals from kits, and the administration of radiopharmaceuticals for diagnostic purposes to humans.
- iii. Physicians authorized for the therapeutic use of quantities of I-131 greater than 33mCi (1.22GBq) in unsealed form are also authorized to use therapeutic use of quantities of I-131 less than 33mCi (1.22GBq) in unsealed form.

F. The Authorized Medical Physicist [15A NCAC 11.0318(a)] for activities authorized under this license shall be Scott Urquhart, MMSc, MS. H.

G. The Radiation Safety Officer for the activities authorized by this license shall be Kenneth R. McBride.

18. For a period not to exceed 60 days in any calendar year, a visiting physician or authorized medical physicist (AMP) is authorized to use the radioactive material under the terms of this license provided the physician or physicist:

- A. Has prior written permission of the hospital administrator and its Radiation Safety Committee; and
- B. Is specifically named as a user or AMP on a N.C. Department of Environment and Natural Resources license, another Agreement State license, US NRC license authorizing use, or is registered as a Qualified Expert with the State of North Carolina pursuant to 15A NCAC 11.0205; and

C. Performs only those procedures for which specifically authorized by a license listed in 18. B. above.

19. Radioactive materials shall not be used on humans without the prior approval (if applicable), in accordance with the provisions of 15A NCAC 11.0356 from an authorized user who is either listed in or satisfies the requirements of Condition No. 17. above, or by a visiting physician who satisfies the requirements of Condition No. 18. above.

20. The licensee is authorized to conduct a decay-in-storage program in accordance with 15A NCAC 11.0362.

21. The licensee shall perform surveys of all areas where radioactive materials and/or radiopharmaceuticals are used, prepared, administered, and/or stored in accordance with 15A NCAC 11.0360.

22. A. The licensee shall establish written procedures for performing use and calibration of dose calibrator(s) used to determine the quantity and quality of radiopharmaceuticals in accordance with 15A NCAC 11.0359

B. Records of the results of the tests outlined in Condition A. above shall be maintained for a minimum of three (3) years following the completion of the test for inspection by the agency.

23. In addition to the possession limits in Item 8 above, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 15A NCAC 11.0353 for establishing decommissioning financial assurance.

24. The licensee shall annually review its Radiation Protection Program for content and implementation [Reference 15A NCAC 11.1603(e)]. Documentation of the Radiation Protection Program reviews shall be retained for inspection by the agency [Reference: 15A NCAC 11.1636].

25. The licensee shall institute the provisions of 15A NCAC 11.1610 when an occupationally exposed woman voluntarily informs her supervisor, in writing, of the pregnancy and the estimated date of conception.

May. 31, 2011 8:03AM:30AM UGH X-RAY

No. 9081 P. 8
No. 2033 P. 4

**RADIOACTIVE MATERIALS BRANCH
RADIATION PROTECTION SECTION
N. C. DEPARTMENT OF ENVIRONMENT AND NATURAL RESOURCES
RADIOACTIVE MATERIALS LICENSE**

Page 4 of 4
License No.: 016-0634-1

CONDITIONS (continued):

26. The licensee shall ensure that no individual "member of the public" [Reference: 15A NCAC 11 .0104(64)] receives a radiation dose in excess of the limits specified in 15A NCAC 11 .1611(A) while conducting licensed activities.
27. Neither this license nor any subsequent amendments shall be deemed to constitute compliance with the requirements for health planning review contained in the Certificate of Need Statute, G.S. 131-175 *et seq.*, and regulations promulgated pursuant to that statute. Inquiries concerning the Certificate of Need Statute should be addressed to the Certificate of Need Section of the Division of Health Service Regulation at (919)855-3883.
28. This license may be subject to amendment, revision, modification, suspension, or revocation in accordance with the provisions of 15A NCAC 11 .0344.
29. In addition to the possession limits referenced in Item 8. above, the licensee shall further restrict possession of radionuclides listed in the table below to the quantities noted within the table. Sum of fractions for the radionuclides listed below shall not exceed unity:

Radionuclide	Quantity (curies)	Radionuclide	Quantity (curies)
Am-241	16	Pm-147	10,800
Am-241/Be	16	Pu-238	16
Cf-252	5.4	Pu-239/Be	16
Cm-244	13.5	Ra-226	10.8
Co-60	8.1	Sc-75	54
Cs-137	27	Sr-90 (Y-90)	270
Gd-153	270	Tm-170	3,400
Ir-192	21.6	Yb-169	81

30. Except as specifically provided otherwise by this license, the licensee shall possess and use radioactive material described in Items 6., 7., and 8. of this license in accordance with statements, representations and procedures and attachments listed below. The North Carolina Regulations for Protection Against Radiation shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application with attachments dated January 7, 2010, signed by P.A. O'Dell, President with facsimiles received January 15, 2010 and telephone calls on January 19, 2010 and January 23, 2010 from H. Scott Urquhart, MMS, MS.

For: W. Lee Cox, III
Chief, Radiation Protection Section

[Signature]